middl
east
respiratori
syndrom
mer
caus
novel
coronaviru
merscov
first
identifi
patient
sever
respiratori
diseas
jordan
saudi
arabia
sinc
discoveri
approxim
case
report
amount
case
per
month
number
low
worrisom
featur
diseas
propens
caus
sever
diseas
patient
underli
condit
includ
diabet
renal
diseas
lung
diseas
immunocompromis
state
appar
abil
readili
spread
within
hospit
set
addit
merscov
identifi
camel
popul
throughout
arabian
peninsula
africa
epidemiolog
evid
suggest
period
introduc
human
popul
coronavirus
welldescrib
propens
mutat
recombin
consist
propens
genom
sequenc
merscov
chang
sinc
first
enter
human
popul
chang
enhanc
abil
effect
humantohuman
transmiss
lack
increas
transmiss
encourag
hand
continu
introduct
human
popul
infect
camel
coupl
coronaviru
mutabl
mean
measur
prevent
infect
import
develop
anticipatorili
follow
demonstr
key
role
hospit
secondari
spread
effort
made
introduc
care
infect
control
measur
affect
hospit
appear
effect
reduc
viru
transmiss
greatli
decreas
number
mer
case
howev
measur
affect
acquisit
primari
case
mer
like
occur
either
directli
indirectli
camel
primari
case
sourc
subsequ
hospit
outbreak
prevent
transmiss
camel
within
commun
might
best
way
provid
subsequ
secondari
case
hospit
spread
addit
appropri
infect
control
measur
viru
transmiss
would
effect
prevent
combin
rapid
effici
diagnosi
treatment
antivir
therapi
decreas
viru
load
prophylact
treatment
intervent
prevent
infect
least
diseas
manifest
often
latter
approach
involv
passiv
activ
immun
discuss
review
effort
prevent
mer
immun
base
part
extens
inform
gain
studi
coronaviru
vaccin
use
prevent
infect
domest
companion
anim
addit
key
piec
inform
requir
ration
design
vaccin
knowledg
protect
immun
respons
immun
respons
nonhuman
coronavirus
character
respons
also
describ
direct
surfac
protein
respons
bind
host
cell
receptor
n
termin
fragment
protein
bind
host
cell
receptor
elicit
neutral
antibodi
perhap
surprisingli
also
part
viru
variabl
isol
variabl
explain
neutral
antibodi
gener
viru
strainspecif
provid
crossreact
protect
even
close
relat
coronavirus
hand
coronavirusspecif
tcell
recogn
epitop
across
genom
conserv
protein
readili
undergo
mutat
prior
onset
sever
acut
respiratori
syndrom
sar
mer
mani
studi
protect
immun
respons
use
mice
infect
murin
coronaviru
mous
hepat
viru
mhv
studi
show
viru
clearanc
infect
mice
requir
develop
effect
tcell
respons
tcell
requir
optim
kinet
clearanc
studi
also
show
tcell
respons
could
immunopatholog
thu
irradi
mice
mice
lack
tand
bcell
infect
strain
mhv
caus
demyelin
mice
develop
minim
clinic
diseas
show
evid
demyelin
howev
within
day
receiv
virusspecif
tcell
sever
myelin
destruct
occur
along
hind
limb
paralysi
neutral
antibodi
also
import
immun
protect
serv
least
two
role
first
absenc
neutral
antibodi
mhv
clear
low
level
tcell
later
recrudesc
result
lethal
diseas
second
virusspecif
antibodi
import
protect
mice
challeng
note
immun
protect
longliv
immunocompet
mice
surviv
experiment
infect
mhv
possibl
infect
system
involv
central
nervou
system
case
liver
mark
contrast
coronavirus
primarili
mucos
induc
shortliv
protect
evid
studi
patient
human
volunt
infect
respiratori
coronavirus
virus
gener
caus
mild
upper
respiratori
tract
diseas
rare
caus
sever
diseas
human
volunt
studi
presenc
preexist
antibodi
provid
protect
experiment
challeng
viru
term
clinic
diseas
viru
titer
similarli
experiment
challeng
provid
partial
protect
subsequ
rechalleng
protect
wane
sever
month
studi
system
antibodi
gener
measur
less
known
level
iga
like
import
protect
virus
remain
confin
upper
respiratori
tract
data
one
might
predict
infect
merscov
sarscov
would
result
longliv
protect
respons
sinc
sarscov
merscov
caus
sever
respiratori
ill
base
lung
sarscov
perhap
merscov
caus
system
infect
howev
may
case
sar
survivor
follow
longitudin
antisarscov
antibodi
titer
detect
year
longitudin
studi
tcell
respons
patient
even
fewer
number
tcell
respons
detect
low
level
survivor
data
suggest
coronavirusspecif
tcell
like
persist
bcell
still
possibl
suffici
number
residu
memori
tand
bcell
protect
patient
infect
sever
diseas
rechalleng
prior
outbreak
sar
coronavirus
consid
import
caus
infect
domest
companion
anim
vaccin
prevent
sever
diseas
develop
year
none
success
prevent
diseas
infecti
bronchiti
viru
ibv
econom
import
infect
young
chicken
caus
bronchiti
well
renal
diseas
review
cavanagh
live
attenu
vaccin
develop
efficaci
provid
shortterm
protect
challeng
homolog
heterolog
ibv
strain
level
circul
ibv
diminish
substanti
mani
strain
ibv
cocircul
chicken
popul
recombin
vaccin
circul
strain
result
emerg
novel
strain
ibv
live
attenu
vaccin
also
develop
swine
coronaviru
transmiss
gastroenter
viru
tgev
caus
fatal
diarrhea
associ
high
mortal
young
pig
vaccin
administ
pregnant
sow
protect
piglet
great
extent
use
virul
viru
sow
success
protect
babi
anim
lethal
diseas
remark
howev
delet
variant
tgev
porcin
respiratori
coronaviru
prc
appear
swine
popul
north
america
eurasia
prc
caus
mild
respiratori
diseas
induc
immun
respons
crossreact
protect
tgev
result
disappear
tgev
local
final
felin
infecti
periton
viru
fipv
caus
lethal
granulomat
diseas
domest
cat
felin
wet
pyogranulomat
effus
dri
classic
granulomat
form
fip
uncommon
often
occur
anim
chronic
infect
felin
coronaviru
fcv
mutat
cours
persist
vaccinia
virusbas
vaccin
express
fipv
surfac
glycoprotein
develop
shown
induc
high
level
antifipv
neutral
antibodi
howev
anti
antibodi
protect
challeng
virul
fipv
rather
induc
antibodydepend
acceler
enhanc
diseas
challeng
note
antibodydepend
enhanc
never
observ
natur
infect
felin
possibl
might
develop
concern
vaccin
sarscov
merscov
develop
vaccin
use
prevent
sar
mer
develop
base
inform
learn
studi
describ
tabl
sar
mer
tend
spread
extens
within
hospit
set
initi
effort
direct
develop
reagent
could
use
passiv
immun
recent
effort
focus
method
use
activ
immun
section
vaccin
target
sarscov
describ
first
sinc
mani
approach
use
develop
mer
vaccin
initi
investig
context
sar
monoclon
antibodi
mab
neutral
activ
sarscov
isol
nonimmun
human
volunt
advantag
approach
protect
antibodi
isol
clone
propag
without
need
obtain
patient
specimen
approach
includ
identifi
clone
memori
bcell
obtain
sar
survivor
amplifi
produc
potent
neutral
antibodi
vaccin
neutral
antibodi
direct
protein
stockpil
antisarscov
antibodi
would
especi
use
healthcar
famili
set
provid
prophylaxi
treatment
administ
soon
exposur
convalesc
sera
sar
survivor
also
use
treat
patient
efficaci
demonstr
may
well
reflect
administr
sera
diseas
alreadi
develop
clinic
present
sar
nonspecif
make
difficult
identifi
infect
patient
earli
time
diseas
cours
convalesc
sera
would
use
outbreak
set
larg
fraction
patient
respiratori
diseas
might
expect
sar
therefor
benefit
treatment
similar
strategi
use
isol
amplifi
antibodi
merscov
neutral
activ
initi
report
describ
isol
neutral
antibodi
human
antibodi
popul
use
phage
display
yeast
display
anoth
approach
mab
high
avid
merscov
protein
isol
bcell
harvest
mer
patient
clone
mammalian
express
system
antibodi
shown
effici
acceler
kinet
viru
clearanc
diminish
patholog
chang
mice
infect
merscov
mice
natur
infect
merscov
viru
use
mous
merscov
receptor
dipeptidyl
peptidas
enter
cell
instanc
mice
sensit
merscov
prior
transduct
adenoviru
engin
express
human
anoth
approach
fulli
human
antibodi
merscov
neutral
activ
develop
use
mice
express
human
antibodi
heavi
k
light
chain
studi
efficaci
examin
mice
engin
express
lieu
knockin
ki
mice
human
anti
mab
acceler
viru
clearanc
reduc
patholog
chang
mous
lung
use
convalesc
sera
mer
survivor
propos
base
studi
sar
patient
howev
limit
avail
convalesc
sera
may
make
use
infeas
camel
consid
primari
reservoir
human
mer
appear
period
reinfect
viru
consequ
merscov
antibodi
titer
elev
administr
sera
previous
infect
camel
merscov
challeng
mice
shown
acceler
merscov
clearanc
reduc
patholog
chang
lung
vaccin
direct
develop
anti
neutral
antibodi
respons
vaccin
includ
inactiv
whole
viru
vaccin
live
attenu
viru
dna
vaccin
viral
vector
vaccin
subunit
vaccin
dna
vaccin
dna
vaccin
shown
induc
anti
antibodi
mice
later
shown
induc
virusspecif
neutral
antibodi
tcell
respons
phase
human
trial
inactiv
sarscov
vaccin
develop
test
experiment
infect
anim
well
phase
human
trial
vaccin
induc
strong
anti
antibodi
respons
administ
adjuv
bpropiolacton
formalin
subsequ
studi
suggest
also
induc
eosinophilia
sign
immunopatholog
diseas
upon
challeng
human
phase
trial
test
reagent
halt
base
put
immunopatholog
chang
live
attenu
vaccin
offer
best
opportun
develop
antibodi
tcell
respons
without
eosinophil
infiltr
manifest
immunopatholog
diseas
lung
engin
live
attenu
vaccin
facilit
develop
revers
genet
system
sarscov
well
coronavirus
includ
merscov
use
one
methodolog
virus
delet
small
envelop
e
protein
develop
virus
shown
attenu
induc
protect
humor
cellbas
immun
respons
hamster
mice
sarscov
challeng
investig
show
vaccin
genet
stabl
partial
duplic
transmembran
protein
detect
upon
repeat
passag
remark
genet
chang
result
reacquisit
pdz
bind
motif
pbm
import
proteinprotein
interact
e
protein
partial
delet
pbm
retain
viru
genet
stabl
attenu
immunogen
anoth
approach
viru
mutat
catalyt
site
protein
critic
genom
fidel
replic
result
attenu
viru
revert
upon
repeat
passag
cell
mice
safe
even
highli
immunocompromis
mice
induc
strong
anti
antibodi
respons
effort
maxim
biosafeti
live
attenu
vaccin
includ
introduct
addit
mutat
nonessenti
protein
noncod
region
genom
rna
minim
likelihood
virul
viru
aris
recombin
circul
coronaviru
strain
attenu
poxviru
adenoviru
adenoassoci
viru
parainfluenza
viru
rabi
viru
measl
viru
vesicular
stomat
viru
vector
express
either
fulllength
sarscov
protein
extracellular
domain
engin
vaccin
also
induc
high
level
sarscov
neutral
antibodi
titer
venezuelan
equin
enceph
viru
replicon
vrp
express
viral
protein
shown
induc
potent
tcell
antibodi
respons
act
selfadjuv
major
advantag
vrp
sinc
nonrepl
infecti
recombin
circul
cov
gener
new
variant
vrp
express
nucleocapsid
n
protein
like
vaccin
found
less
effect
senesc
mice
vrpn
report
induc
immunopatholog
diseas
similar
immunopatholog
observ
sarscov
challeng
mice
previous
immun
n
protein
potent
neutral
antibodi
respons
also
induc
mice
immun
construct
express
receptor
bind
domain
part
sarscov
protein
actual
bind
receptor
angiotensinconvert
enzym
target
cell
subunit
vaccin
exhibit
high
safeti
profil
minim
side
effect
addit
immunogen
mani
approach
describ
use
develop
mer
vaccin
recombin
adenovirus
poxvirus
measl
viru
express
fulllength
protein
extracellular
domain
engin
test
experiment
infect
anim
abl
induc
anti
protein
antibodi
respons
although
examin
like
also
induc
tcell
respons
live
attenu
merscov
vaccin
yet
describ
although
like
base
sarscov
data
viru
mutat
catalyt
site
exonucleas
would
excel
vaccin
candid
dna
vaccin
induc
merscovspecif
antibodi
tcell
respons
describ
shown
efficaci
nonhuman
primat
vaccin
express
merscov
receptor
bind
domain
rbd
induc
potent
neutral
antibodi
mice
neutral
antibodi
tcell
respons
nonhuman
primat
vaccin
result
acceler
viru
clearanc
diminish
patholog
chang
prevent
infect
vaccin
develop
usual
target
human
popul
merscov
infect
much
greater
number
higher
percentag
camel
human
arabian
peninsula
africa
thu
camel
vaccin
approach
decreas
amount
circul
viru
also
diminish
amount
viru
secret
infect
anim
recent
studi
show
approach
feasibl
camel
immun
orthopoxviru
vector
modifi
vaccinia
viru
ankara
mva
express
protein
challeng
merscov
week
boost
clinic
sign
rhiniti
infecti
viru
titer
upper
respiratori
tract
main
site
replic
camel
diminish
immun
compar
control
anim
sever
promis
mer
vaccin
candid
develop
sever
issu
need
resolv
first
import
consider
whether
human
altern
camel
vaccin
human
camel
develop
sever
respiratori
diseas
rel
small
total
number
infect
individu
identifi
mani
comorbid
would
impair
vaccin
respons
absenc
greater
diseas
burden
human
popul
seem
unlik
human
vaccin
would
ever
econom
viabl
hand
high
percentag
camel
infect
merscov
vaccin
reduc
viru
load
although
without
induc
steril
immun
longev
camel
immun
respons
known
may
short
sinc
camel
appear
readili
reinfect
merscov
larg
size
camel
plu
number
camel
potenti
requir
immun
would
caus
logist
problem
second
vaccin
induc
anti
neutral
antibodi
respons
receptor
bind
part
protein
target
neutral
antibodi
variabl
part
protein
antibodi
highli
strainspecif
protein
merscov
shown
evid
mutat
result
antibodi
evas
still
possibl
coronavirus
prone
mutat
recombin
thu
target
protein
may
provid
protect
merscov
may
use
either
close
relat
strain
one
evolv
respons
immun
pressur
human
possibl
highlight
recent
studi
show
two
bat
strain
sarslik
cov
close
relat
human
sarscov
use
receptor
enter
cell
howev
antisarscov
antibodi
could
neutral
one
strain
third
tcell
respons
mer
sar
survivor
investig
wide
tend
target
conserv
region
viral
genom
provid
protect
strain
differ
rbd
analysi
tcell
respons
facilit
identif
tcell
epitop
tcell
epitop
identifi
inbr
strain
mice
difficult
identifi
human
popul
interindividu
human
leukocyt
antigen
hla
divers
extent
vaccin
formul
induc
tcell
respons
well
neutral
antibodi
respons
yet
resolv
fourth
prior
use
human
vaccin
need
care
evalu
experiment
infect
anim
laboratori
anim
infect
merscov
develop
diseas
pathogenesi
occur
patient
sever
respiratori
diseas
marmoset
develop
sever
diseas
laboratori
set
even
lethal
mouseadapt
merscov
identifi
diseas
mous
untoward
effect
vaccin
may
mirror
human
infect
suffici
better
anim
model
mer
would
facilit
use
accur
vivo
vaccin
evalu
conclus
learn
ebola
pandem
prepared
epidem
spread
viru
never
exhibit
spread
past
critic
far
upsurg
mer
case
hajj
umrah
pilgrimag
nevertheless
consider
develop
tool
passiv
activ
immun
critic
